Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant.

Averbuch, Mordechai; Levo, Y

doi:10.1136/ard.45.5.435

Cited by 36 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 The thrombotic events in AP involve the hepatic circulation, most frequently as the BuddChiari syndrome. [6][7][8][9][10][11][12][13] There are three previous reports of APS and portal vein thrombosis [14][15][16] in which patients had severe symptoms associated with portal thrombosis, esophageal varices from portal hypertension, 14,15 or hepatic infarction, 16 whereas our patient had only nonspecific but common symptoms, such as abdominal pain and fever. Moreover, his portal thrombus disappeared spontaneously (Fig.…”

Section: Discussionmentioning

confidence: 47%

Portal vein thrombosis associated with antiphospholipid syndrome

Hirohata

Murata

Abe

et al. 2001

Journal of Gastroenterology

View full text Add to dashboard Cite

Portal vein thrombosis is a rare occurrence, and often an underlying hypercoagulable state can be found. Recently, there has been growing interest and recognition of the antiphospholipid syndrome in association with acquired hypercoagulable state. This syndrome consists of the association of lupus anticoagulant or antiphospholipid antibodies with arterial or venous thrombosis, thrombocytopenia, and spontaneous abortion. We report a case of portal vein thrombosis associated with the antiphospholipid syndrome. In our patient, chronic liver disease, hepatobiliary infection, abdominal malignancies, myeloproliferative disorders, and inherited coagulation disorders were excluded. This case report suggests that serum antiphospholipid antibodies should be investigated in patients with portal vein thrombosis of unexplained etiology.

show abstract

Section: Discussionmentioning

confidence: 47%

Portal vein thrombosis associated with antiphospholipid syndrome

Hirohata

Murata

Abe

et al. 2001

Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Seven reports of hepatic vein occlusion resulting in Budd-Chiari syndrome have been published. [21][22][23][24][25][26][27] The antibodies may also be of importance in the pathogenesis of other hepatic lesions, some of which have a vascular basis and involve smaller intrahepatic vessels. 28 In 1998 Perez-Ruiz et al suggested a possible role of the aPL in the pathogenesis of nodular regenerative hyperplasia of the liver (NRHL).…”

Section: Primary Antiphospholipid Antibody Syndromementioning

confidence: 99%

Hepatic manifestations of autoimmune rheumatic diseases

Abraham

Begum²,

Isenberg³

2004

Annals of the Rheumatic Diseases

176

107

View full text Add to dashboard Cite

“…18 The association of this syndrome with lupus anticoagulant was reported in one patient in 1984 but the patient did not fulfill the required criteria proposed for the diagnosis of SLE. 19 Our patient satisfied the criteria proposed for the diagnosis of SLE; here the cause of hepatic vein thrombosis is the presence of lupus anticoagulant that interferes with the normal function of blood vessels causing vasculopathy and ultimately thrombosis.…”

Section: Discussionmentioning

confidence: 99%

Budd Chiari Syndrome in a Fifteen-Year Old Girl with Systemic Lupus Erythematosus

Hussain¹,

Jaffery²,

Sabri³

et al. 2009

Int J Health Res

View full text Add to dashboard Cite

an online international journal allowing free unlimited access to abstract and full-text of published articles. The journal is devoted to the promotion of health sciences and related disciplines (including medicine, pharmacy, nursing, biotechnology, cell and molecular biology, and related engineering fields). It seeks particularly (but not exclusively) to encourage multidisciplinary research and collaboration among scientists, the industry and the healthcare professionals. It will also provide an international forum for the communication and evaluation of data, methods and findings in health sciences and related disciplines. The journal welcomes original research papers, reviews and case reports on current topics of special interest and relevance. All manuscripts will be subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication) will be published without delay. The maximum length of manuscripts should normally be 10,000 words (20 single-spaced typewritten pages) for review, 6,000 words for research articles, 3,000 for technical notes, case reports, commentaries and short communications. Submission of Manuscript:The International Journal of Health Research uses a journal management software to allow authors track the changes to their submission. All manuscripts must be in MS Word and in English and should be submitted online at http://www.ijhr.org. Authors who do not want to submit online or cannot submit online should send their manuscript by e-mail attachment (in single file) to the editorial office below. Submission of a manuscript is an indication that the content has not been published or under consideration for publication elsewhere. Authors may submit the names of expert reviewers or those they do not want to review their papers. Enquiries

show abstract

Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant.

Cited by 36 publications

References 13 publications

Portal vein thrombosis associated with antiphospholipid syndrome

Portal vein thrombosis associated with antiphospholipid syndrome

Hepatic manifestations of autoimmune rheumatic diseases

Budd Chiari Syndrome in a Fifteen-Year Old Girl with Systemic Lupus Erythematosus

Contact Info

Product

Resources

About